| Covidien Buys Ev3 for $2.6 Billion Covidien said it is buying vascular device maker ev3 for $2.6 billion in cash as it continues to remake its business. online.wsj.com |
Cord Blood America Details Six Months of Success (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced highlights for the six-month period ended June 30, 2010. us.rd.yahoo.com |
FDA Proposes To Remove Shire Drug From Market The FDA proposed to remove from the market a low-blood pressure drug originally developed by Shire, saying required follow-up clinical studies showing the drug works haven't been conducted. online.wsj.com |
Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010 [PR Newswire] - Tengion, Inc. , a leader in regenerative medicine, today announced that it will host an Analyst and Investor Meeting on Wednesday, October 27, 2010 in New York, New York. Tengion's management team will provide an update on the Company's product development portfolio and upcoming corporate milestones, and will expand on recently presented data from the Neo-Kidney Augmentâ„¢ program. us.rd.yahoo.com |
U.K. Cost Body Declines to Back Cancer Drug The U.K. health-cost body has declined to back Novartis's kidney-cancer drug Afinitor as a second line treatment due to lingering cost and efficiency concerns. online.wsj.com |